Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer
Chaoyang Li, … , Wei Xin, Man-Sun Sy
Chaoyang Li, … , Wei Xin, Man-Sun Sy
Published August 17, 2009
Citation Information: J Clin Invest. 2009;119(9):2725-2736. https://doi.org/10.1172/JCI39542.
View: Text | PDF
Research Article Oncology

Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer

  • Text
  • PDF
Abstract

The cellular prion protein (PrP) is a highly conserved, widely expressed, glycosylphosphatidylinositol-anchored (GPI-anchored) cell surface glycoprotein. Since its discovery, most studies on PrP have focused on its role in neurodegenerative prion diseases, whereas its function outside the nervous system remains unclear. Here, we report that human pancreatic ductal adenocarcinoma (PDAC) cell lines expressed PrP. However, the PrP was neither glycosylated nor GPI-anchored, existing as pro-PrP and retaining its GPI anchor peptide signal sequence (GPI-PSS). We also showed that the PrP GPI-PSS has a filamin A–binding (FLNa-binding) motif and interacted with FLNa, an actin-associated protein that integrates cell mechanics and signaling. Binding of pro-PrP to FLNa disrupted cytoskeletal organization. Inhibition of PrP expression by shRNA in the PDAC cell lines altered the cytoskeleton and expression of multiple signaling proteins; it also reduced cellular proliferation and invasiveness in vitro as well as tumor growth in vivo. A subgroup of human patients with pancreatic cancer was found to have tumors that expressed pro-PrP. Most importantly, PrP expression in tumors correlated with a marked decrease in patient survival. We propose that binding of pro-PrP to FLNa perturbs FLNa function, thus contributing to the aggressiveness of PDAC. Prevention of this interaction could provide an attractive target for therapeutic intervention in human PDAC.

Authors

Chaoyang Li, Shuiliang Yu, Fumihiko Nakamura, Shaoman Yin, Jinghua Xu, Amber A. Petrolla, Neena Singh, Alan Tartakoff, Derek W. Abbott, Wei Xin, Man-Sun Sy

×

Figure 4

Downregulation of PrP or FLNa expression in the PDAC cell lines.

Options: View larger image (or click on image) Download as PowerPoint
Downregulation of PrP or FLNa expression in the PDAC cell lines.
(A) Imm...
(A) Immunofluorescence staining and confocal microscopic images show the PDAC cell lines with shRNA-10 have reduced levels of PrP. Original magnification, ×1,000. (B) Immunoblots show the PrP-downregulated shRNA-10 cells have reduced levels of PrP. (C) Immunoblots show the level of FLNa does not change in PrP-downregulated cells. (D) Immunofluorescence staining and confocal microscopic images show that knocking down PrP alters the spatial distribution of FLNa. Arrows show staining of membrane ruffles and leading edges. Original magnification, ×1,000. (E) Immunoblots show that when expression of FLNa is inhibited, the expression of PrP is also reduced in Panc 02.03 cells. (F) Immunofluorescence staining and confocal microscopic images show the expression of FLNa modulates PrP but not CD55 expression. In the top left panel, the dashed arrow identifies a cell with FLNa (green); solid arrows identify 2 cells lacking FLNa. In the top center panel, 2 solid arrows identify 2 cells lacking PrP; the dashed arrow identifies 1 cell with PrP (red). The top right panel is the merge of the left and center panels; 2 arrows identify 2 cells lacking both PrP and FLNa, and a dashed arrow identifies 1 cell with both PrP and FLNa. In the bottom panels, 2 FLNa-negative cells (left panel, solid arrows) still express high levels of CD55 (red; center panel, solid arrows), although some cells have both FLNa and CD55 stain (left and center panels, dashed arrows). Original magnification, ×1,000.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts